Faron Pharmaceuticals Valuation
| FARN Stock | 170.00 2.50 1.49% |
At this time, the firm appears to be overvalued. Faron Pharmaceuticals shows a prevailing Real Value of USD142.8 per share. The current price of the firm is USD170.0. Our model computes the value of Faron Pharmaceuticals from reviewing the firm fundamentals such as Current Valuation of 163.6 M, shares owned by insiders of 31.81 %, and Price To Sales of 16.21 X as well as analyzing its technical indicators and probability of bankruptcy.
Price Book 156.0929 | Enterprise Value 163.6 M | Enterprise Value Ebitda (3.53) | Price Sales 16.209 |
Overvalued
Today
Please note that Faron Pharmaceuticals' price fluctuation is very steady at this time. Calculation of the real value of Faron Pharmaceuticals is based on 3 months time horizon. Increasing Faron Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Faron stock is determined by what a typical buyer is willing to pay for full or partial control of Faron Pharmaceuticals Oy. Since Faron Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Faron Stock. However, Faron Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 170.0 | Real 142.8 | Hype 170.0 | Naive 154.38 |
The intrinsic value of Faron Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Faron Pharmaceuticals' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Faron Pharmaceuticals Oy helps investors to forecast how Faron stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Faron Pharmaceuticals more accurately as focusing exclusively on Faron Pharmaceuticals' fundamentals will not take into account other important factors: Faron Pharmaceuticals Cash |
|
Faron Pharmaceuticals Total Value Analysis
Faron Pharmaceuticals Oy is currently projected to have takeover price of 163.6 M with market capitalization of 177.86 M, debt of 13.11 M, and cash on hands of . Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Faron Pharmaceuticals fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
163.6 M | 177.86 M | 13.11 M |
Faron Pharmaceuticals Asset Utilization
One of the ways to look at asset utilization of Faron is to check how much profit was generated for every dollar of assets it reports. Faron Pharmaceuticals Oy shows a negative utilization of assets of -0.7 percent, losing USD0.007 for each dollar of assets held by the firm. Inadequate asset utilization denotes the company is being less effective with each dollar of assets it shows. Put another way, asset utilization of Faron Pharmaceuticals Oy shows how discouraging it operates for each dollar spent on its assets.Faron Pharmaceuticals Ownership Allocation
Faron Pharmaceuticals holds a total of 104.62 Million outstanding shares. Faron Pharmaceuticals Oy retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Faron Pharmaceuticals Profitability Analysis
Net Loss for the year was (30.94 M) with profit before overhead, payroll, taxes, and interest of 803 K.About Faron Pharmaceuticals Valuation
The stock valuation mechanism determines Faron Pharmaceuticals' current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Faron Pharmaceuticals based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Faron Pharmaceuticals. We calculate exposure to Faron Pharmaceuticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Faron Pharmaceuticals's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 17.1 K | 16.2 K |
Additional Tools for Faron Stock Analysis
When running Faron Pharmaceuticals' price analysis, check to measure Faron Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Faron Pharmaceuticals is operating at the current time. Most of Faron Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Faron Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Faron Pharmaceuticals' price. Additionally, you may evaluate how the addition of Faron Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.